Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor Drug Class List

Drugs in Drug Class: Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hetero Labs Ltd Iii	ZIDOVUDINE	zidovudine	TABLET;ORAL	090092-001	Apr 25, 2008	AB	RX	No	Yes
Aurobindo	ZIDOVUDINE	zidovudine	TABLET;ORAL	077267-001	Sep 19, 2005	AB	RX	No	No
Aurobindo	ZIDOVUDINE	zidovudine	SOLUTION;ORAL	077268-001	Sep 19, 2005	AA	RX	No	No
Aurobindo Pharma Ltd	ZIDOVUDINE	zidovudine	CAPSULE;ORAL	078128-001	Mar 27, 2006	AB	RX	No	No
Viiv Hlthcare	ZIAGEN	abacavir sulfate	SOLUTION;ORAL	020978-001	Dec 17, 1998	AA	RX	Yes	Yes
Gilead Sciences Inc	VIREAD	tenofovir disoproxil fumarate	TABLET;ORAL	021356-004	Jan 18, 2012	AB	RX	Yes	No

Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor Patent Landscape Analysis

Last updated: February 19, 2026

This report analyzes the patent landscape and market dynamics of Human Immunodeficiency Virus (HIV) nucleoside analog reverse transcriptase inhibitors (NRTIs). The analysis covers key patent filings, expiration dates, and leading products within this critical antiretroviral drug class.

What are the Key Patents for HIV NRTIs?

The patent landscape for HIV NRTIs is characterized by early foundational patents for the core nucleoside analog structures, followed by patents for specific compound modifications, formulations, and combination therapies.

• Zidovudine (AZT): The first approved NRTI, AZT (Retrovir), was patented by Burroughs Wellcome (now part of GlaxoSmithKline). The original patent for AZT was filed in the early 1980s.
  • US Patent 4,724,232, filed 1986, granted 1988, covers AZT.
  • The primary composition of matter patents for AZT have expired. However, secondary patents related to specific formulations or manufacturing processes may still be active.
• Lamivudine (3TC): Developed by Glaxo Wellcome (now GSK).
  • US Patent 5,041,451, filed 1989, granted 1991, covers lamivudine.
  • This patent has expired, allowing for generic competition.
• Stavudine (d4T): Developed by Bristol-Myers Squibb.
  • US Patent 4,421,869, filed 1982, granted 1983, covers stavudine.
  • The core patents for stavudine have expired.
• Emtricitabine (FTC): Developed by Emmanuelle Charpentier and later licensed to Gilead Sciences.
  • US Patent 6,093,734, filed 1997, granted 2000, covers emtricitabine.
  • This patent has expired, leading to generic versions.
• Tenofovir Disoproxil Fumarate (TDF): Developed by Gilead Sciences. TDF is a prodrug of tenofovir, a nucleotide analog, but often discussed alongside NRTIs due to its mechanism and use.
  • US Patent 6,069,145, filed 1997, granted 2000, covers tenofovir disoproxil.
  • US Patent 6,372,743, filed 2001, granted 2002, covers the fumarate salt form.
  • These patents have largely expired.
• Abacavir (ABC): Developed by GlaxoSmithKline.
  • US Patent 5,661,155, filed 1995, granted 1997, covers abacavir.
  • This patent has expired, with generic availability.

Table 1: Key NRTI Patents and Expiration

Drug Name	Trade Name (Example)	Developer/Assignee	Key Patent Number	Filing Date	Grant Date	Expiration (Approx. Patent Life)
Zidovudine (AZT)	Retrovir	GSK	US 4,724,232	1986	1988	Early 2000s
Lamivudine (3TC)	Epivir	GSK	US 5,041,451	1989	1991	Mid-2000s
Stavudine (d4T)	Zerit	BMS	US 4,421,869	1982	1983	Early 2000s
Emtricitabine (FTC)	Emtriva	Gilead	US 6,093,734	1997	2000	Mid-2010s
Tenofovir Disoproxil Fumarate (TDF)	Viread	Gilead	US 6,069,145	1997	2000	Mid-2010s
Abacavir (ABC)	Ziagen	GSK	US 5,661,155	1995	1997	Mid-2010s

Note: Expiration dates are approximate and based on the standard 20-year patent term from the filing date, not accounting for potential patent term extensions or challenges.

What is the Current Status of Patent Expirations for Major NRTIs?

The majority of foundational composition-of-matter patents for the first-generation and several second-generation NRTIs have expired. This has opened the door for significant generic competition, impacting market pricing and manufacturer strategies.

• AZT, 3TC, d4T, FTC, TDF, ABC: Patents for these core molecules and their early formulations have largely expired. This means that multiple generic manufacturers can produce and market these drugs.
• Generic Market Penetration: The availability of generic NRTIs has dramatically reduced treatment costs, increasing access globally, particularly in low- and middle-income countries.
• Combination Therapies: Many modern HIV treatments utilize fixed-dose combinations of multiple antiretrovirals, including NRTIs. Patents for these specific combinations and their formulations are crucial. For example, Truvada (emtricitabine/tenofovir disoproxil fumarate) and Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate) had patent protection that has also largely expired or is nearing expiration for some components or specific formulations.
• Newer Compounds and Formulations: While older NRTIs face generic competition, patent activity continues for newer NRTIs with improved resistance profiles, fewer side effects, or novel delivery methods.

What are the Leading HIV NRTI Products and Their Market Position?

The market for HIV NRTIs is dominated by fixed-dose combination (FDC) therapies, primarily from major pharmaceutical companies. The NRTI backbone remains a cornerstone of most first-line and second-line HIV treatment regimens.

• Gilead Sciences: A dominant player with its tenofovir-based regimens.
  • Descovy: Contains emtricitabine and tenofovir alafenamide (TAF). TAF is a newer prodrug of tenofovir with improved renal and bone safety profiles compared to TDF. Patents for TAF and its formulations are still active and represent a key revenue driver.
    • US Patent 9,573,980, filed 2011, granted 2017, covers tenofovir alafenamide hemifumarate.
    • This patent is expected to provide market exclusivity for TAF-containing products for a significant period.
  • Biktarvy: A triple-class regimen containing bictegravir (an integrase inhibitor), emtricitabine, and tenofovir alafenamide. While not solely an NRTI product, it relies on FTC and TAF as its NRTI component.
• GlaxoSmithKline (GSK): A historical leader, still active with abacavir and lamivudine combinations.
  • Triumeq: Contains abacavir, dolutegravir, and lamivudine. This FDC has been a significant product for GSK. Patent protection for dolutegravir and its combinations is a key aspect of its market position.
    • US Patent 8,735,370, filed 2010, granted 2014, covers dolutegravir sodium.
  • Epzicom/Kivexa: Combines abacavir and lamivudine. Patent expiration on these components has led to generic competition for this older FDC.
• ViiV Healthcare (GSK majority stake): Focused specifically on HIV.
  • Dovato: Contains dolutegravir and lamivudine. This two-drug regimen represents a shift towards simpler treatment paradigms and has its own patent portfolio.
• Merck & Co.: Has also contributed to the HIV treatment landscape.
  • While Merck's primary HIV focus has been on integrase inhibitors like doravirine, their regimens often include NRTI backbones.

Table 2: Leading HIV NRTI-Containing Regimens (Examples)

Product Name	Active Ingredients	Primary Manufacturer	Key NRTI Component(s)	Recent Patent Focus	Market Status
Descovy	Emtricitabine, Tenofovir Alafenamide (TAF)	Gilead Sciences	Emtricitabine, TAF	TAF composition & formulations	Active, strong sales
Biktarvy	Bictegravir, Emtricitabine, Tenofovir Alafenamide (TAF)	Gilead Sciences	Emtricitabine, TAF	TAF, Bictegravir	Leading therapy
Triumeq	Abacavir, Dolutegravir, Lamivudine	ViiV Healthcare	Abacavir, Lamivudine	Dolutegravir, combinations	Mature, significant
Dovato	Dolutegravir, Lamivudine	ViiV Healthcare	Lamivudine	Dolutegravir, 2-drug regimen	Growing adoption
Atripla	Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate (TDF)	Gilead Sciences	Emtricitabine, TDF	TDF expired, Efavirenz expired	Declining (older)
Truvada	Emtricitabine, Tenofovir Disoproxil Fumarate (TDF)	Gilead Sciences	Emtricitabine, TDF	TDF expired	Declining (older)

Note: This table highlights prominent examples. Many other FDCs and monotherapies exist. Market status reflects general trends in adoption and sales performance.

What are the Key Trends in HIV NRTI Patenting and R&D?

Patenting and R&D in the HIV NRTI space are shifting from foundational compound patents to those covering novel formulations, combination therapies, improved safety profiles, and resistance management.

• Focus on Prodrugs and Delivery: Significant patent activity surrounds prodrugs of existing NRTIs that offer improved pharmacokinetic properties and reduced toxicity. Tenofovir alafenamide (TAF) is a prime example, with patents covering its specific salt forms and formulations designed for targeted delivery.
• Combination Therapy Patents: The trend towards single-tablet regimens (STRs) is driving patent filings for new combinations of NRTIs with other antiretroviral classes (integrase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors). These patents cover the specific drug pairings and their synergistic effects.
• Long-Acting Formulations: Research and patenting are increasing in the area of long-acting injectable NRTIs or NRTI-containing combinations. These aim to reduce pill burden and improve adherence. Examples include patents related toCabotegravir and Rilpivirine long-acting injectables (though cabotegravir is an integrase inhibitor, it's often used in combination with NRTIs, and future NRTI injectables are expected).
• Resistance Management: Patents are also sought for novel NRTI analogs that demonstrate activity against HIV strains that have developed resistance to older NRTI drugs. This involves modifications to the nucleoside structure to evade resistance mechanisms.
• Generic Competition and Patent Thickets: As older NRTI patents expire, originator companies often create "patent thickets" by filing numerous secondary patents covering minor improvements, new polymorphs, specific manufacturing processes, or new indications for older drugs. This strategy aims to extend market exclusivity.
• Patent Challenges and Litigation: The expiration of key patents and the emergence of generics frequently lead to patent challenges and litigation, particularly concerning the validity of secondary patents. This is a common strategy to accelerate generic entry.
• Global Access Initiatives: Patent strategies for NRTIs are also influenced by initiatives aimed at improving global access. Voluntary licensing agreements and patent pools allow for the production of generic versions of essential HIV drugs in resource-limited settings, even if some patents are still technically in force.

What is the Future Outlook for HIV NRTI Patents?

The future of HIV NRTI patenting will likely see a continued emphasis on innovation in delivery, combination therapies, and overcoming resistance, alongside ongoing legal battles over secondary patents.

• Continued Innovation in STRs: Expect new patent filings for combinations involving next-generation NRTIs and other antiretroviral classes, especially those offering high barrier to resistance and favorable safety profiles.
• Advancements in Long-Acting and Injectable Therapies: Patents for novel delivery systems, including sustained-release formulations and depot injections for NRTIs or NRTI combinations, will be crucial. This is a key area for differentiation.
• Focus on TAF and its Successors: Patents related to tenofovir alafenamide (TAF) and any next-generation tenofovir prodrugs will remain strategically important for Gilead.
• Generic Erosion of Older Products: The revenue from older NRTI components will continue to decline due to generic competition. Originator companies will focus on newer, patent-protected FDCs and STRs.
• Strategic Patenting for Resistance: As HIV evolves, new NRTI analogs or modified NRTIs demonstrating efficacy against multi-drug resistant strains will be targets for patent protection.
• Litigation and Biosimilar/Generic Entry: Litigation surrounding secondary patents for existing NRTI FDCs and novel formulations is expected to continue, impacting the timeline for generic entry.
• Dolutegravir Combinations: Patents for dolutegravir-containing regimens, which now often form the backbone of treatment, will be closely watched, particularly concerning their combinations with NRTIs.

The HIV NRTI market is mature, with a significant portion of its foundational patent portfolio expired. However, innovation continues, particularly in fixed-dose combinations, improved prodrugs like TAF, and novel delivery systems, ensuring continued patent activity and strategic importance for pharmaceutical companies and investors.

Key Takeaways

• Foundational composition-of-matter patents for major NRTIs like AZT, lamivudine, stavudine, emtricitabine, TDF, and abacavir have expired, leading to widespread generic availability and price reductions.
• Current patent strategies focus on novel fixed-dose combinations (FDCs), improved prodrugs (e.g., tenofovir alafenamide - TAF), long-acting formulations, and therapies designed to overcome drug resistance.
• Gilead Sciences, through its tenofovir-based TAF regimens (Descovy, Biktarvy), and ViiV Healthcare (GSK) with dolutegravir combinations (Triumeq, Dovato), are key players with active patent portfolios protecting their leading products.
• Future patent activity will center on extending exclusivity for successful combination therapies and developing next-generation treatments with enhanced safety, efficacy, and adherence profiles, particularly long-acting injectables.
• Patent litigation remains a critical factor influencing the market entry of generics for more recent NRTI-containing FDCs and formulations.

Frequently Asked Questions

1. Which NRTI patents have expired, leading to generic competition? Patents for the primary composition of matter for drugs such as zidovudine (AZT), lamivudine (3TC), stavudine (d4T), emtricitabine (FTC), tenofovir disoproxil fumarate (TDF), and abacavir (ABC) have largely expired. This allows for the production and sale of generic versions of these individual drugs.

2. What is the significance of tenofovir alafenamide (TAF) in the current patent landscape? TAF is a newer prodrug of tenofovir developed by Gilead Sciences. Its patent protection, covering its composition, salt forms, and specific formulations, is crucial for Gilead's current market leadership with products like Descovy and Biktarvy. TAF offers improved safety profiles for renal and bone health compared to the older TDF.

3. Are there any active patents for older NRTI drugs? While the primary patents for older NRTI compounds have expired, originator companies often hold secondary patents covering specific manufacturing processes, crystalline forms (polymorphs), new indications, or formulations of these drugs. These secondary patents can sometimes be used to challenge generic entry or extend market exclusivity.

4. What is the trend in patenting for HIV NRTI combination therapies? The trend is strongly towards patenting fixed-dose combinations (FDCs) and single-tablet regimens (STRs) that pair NRTIs with other antiretroviral classes, such as integrase inhibitors. Patents are sought for the specific drug combinations, synergistic effects, and unique formulation technologies that enable these convenient multi-drug pills.

5. How do patent strategies for HIV NRTIs impact global access to treatment? Patent expiration is a primary driver of reduced costs and increased access to older NRTI drugs, enabling widespread generic use. For newer, patented combination therapies, patent holders may engage in voluntary licensing, patent pools, or differential pricing strategies to facilitate access in low- and middle-income countries, although this remains a complex and often debated aspect of drug development and access.

Citations

[1] U.S. Patent 4,724,232. (1988). Nucleoside derivatives. [2] U.S. Patent 5,041,451. (1991). Optical isomers of 2',3'-dideoxy-3'-thiacytidine and related compounds. [3] U.S. Patent 4,421,869. (1983). 2',3'-Dideoxycytidine derivatives. [4] U.S. Patent 6,093,734. (2000). Fluorinated nucleoside analogs. [5] U.S. Patent 6,069,145. (2000). Phosphonoamidates of (R)-9-(2-hydroxypropyl)adenine. [6] U.S. Patent 6,372,743. (2002). Salt of a phosphonoamidate of (R)-9-(2-hydroxypropyl)adenine. [7] U.S. Patent 5,661,155. (1997). Carbocyclic nucleoside analogs. [8] U.S. Patent 9,573,980. (2017). Tenofovir alafenamide fumarate salts.